# RESPIRERX PHARMACEUTICALS INC.: Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | RESPIRERX PHARMACEUTICALS INC. |
| Location | GLEN ROCK, NJ |
| Project | Development of a novel, preferring potentiator of GABAA receptor for treatment of epilepsy |
| Project number | 5R44NS143576-02 |
| Mechanism | R44 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $1,499,869 |
| Awarded | 2026-09-14 |
| Project period | 2025-09-23 to 2027-08-31 |
| UEI | HWS8C3MQDTH7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11420545). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.